+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Western blot analysis using ACADM mouse mAb against Hela (1), HepG2 (2),Jurkat (3),Raji (4) and K562 (5) cell lysate.    

  
  

•  

   

     Immunofluorescence analysis of Hela cells using ACADM mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin. Secondary antibody from Fisher (Cat#: 35503)    

  
  

•  

   

     Flow cytometric analysis of HL-60 cells using ACADM mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human cervical carcinoma tissues using ACADM mouse mAb with DAB staining.    

  
  

The ACADM (acyl-CoA dehydrogenase medium chain) antibody is a crucial tool in studying mitochondrial fatty acid β-oxidation, a metabolic pathway essential for energy production. ACADM encodes the medium-chain acyl-CoA dehydrogenase enzyme, which catalyzes the initial step of breaking down medium-chain fatty acids (C6-C12). Mutations in the ACADM gene cause medium-chain acyl-CoA dehydrogenase deficiency (MCADD), an autosomal recessive disorder characterized by life-threatening metabolic crises during fasting or illness.

ACADM antibodies are primarily used in research and diagnostics to detect and quantify ACADM protein expression. These antibodies enable techniques like Western blotting, immunohistochemistry, and immunofluorescence, helping identify protein deficiencies in patients with suspected MCADD. They also facilitate studies on tissue-specific ACADM distribution, post-translational modifications, and interactions with other metabolic enzymes.

Commercially available ACADM antibodies are typically developed in animal hosts (e.g., rabbit, mouse) using recombinant protein fragments or synthetic peptides. Their specificity is validated using knockout controls or MCADD patient samples. Beyond basic research, these antibodies contribute to developing targeted therapies and newborn screening methods. However, interpretation requires caution due to potential cross-reactivity with other acyl-CoA dehydrogenase family members. Ongoing efforts aim to improve antibody sensitivity and standardization for clinical applications.